Vivek Vasdev1, S K Patnaik2, D S Bhakuni3, K Shanmuganandan4, A Bhayana5, G Mullick6, A Hegde7, Ashwini Kumar8, Abhishek Kumar9, R Singh10. 1. Professor & Head, Dept of Geriatric Medicine, Armed Forces Medical College, Pune 411040, India. 2. Professor & Senior Advisor (Pediatrics) and Pediatric Nephrologist, Army Hospital (R&R), Delhi Cantt, India. 3. Consultant (Rheumatology) & Clinical Immunology, Manipal Hospital, Dwarka, New Delhi, India. 4. Professor (Medicine), Sree Balaji Medical College, Chrompet, Chennai, India. 5. Graded Specialist (Aerospace Medicine), Air Force Station, Palam, New Delhi, India. 6. Senior Advisor (Medicine) & Rheumatologist, INHS Aswini, Mumbai, India. 7. Senior Advisor (Medicine) & Rheumatologist, Command Hospital (Southern Command), Pune, India. 8. Classified Specialist (Medicine) & Rheumatologist, Army Hospital (R&R), Delhi Cantt, India. 9. Classified Specialist (Medicine) & Rheumatologist, Command Hospital (Eastern Command), Kolkata, India. 10. Classified Specialist (Medicine) & Rheumatologist, INHS Aswini, Mumbai, India.
Abstract
BACKGROUND: Time and cost constraints lead to majority of clinical laboratories deviating away from an ideal practice of checking for antinuclear antibodies (ANAs) by indirect immunofluorescence (IIF) at multiple dilutions. Usage of screening dilution of 1:40 recommended by most manufacturers of commercial ANA kits results in numerous false positive-tests and misdiagnosis of connective tissue disorders (CTDs). We sought to study the ideal screening dilution for ANA by IIF for a diagnosis of ANA-related CTDs. METHODS: Serum samples of patients with ANA-related conditions (n = 233) and healthy controls (n = 154) were evaluated by IIF using Immuno Concepts Hep-2000 ® ANA kits at dilutions from 1:40 to 1:640. Accuracy for diagnosis of CTDs for each serum dilution was assessed by receiver operating curve (ROC) analysis. RESULTS: Antinuclear antibodies (ANA) positivity was observed in 19.5%, 10.4%, 4.55%, 0.65%, and 0% of healthy controls at dilutions of 1:40, 1:80, 1:160, 1:320, and 1:640, respectively. ANA positivity at 1:40 dilution was observed among 26.4% cases with mimics of CTDs. Prevalence of ANA positivity in ANA-related CTDs was 97.3%, 96.4%, 89.3%, 83.9%, and 71.4% at dilutions of 1:40, 1:80, 1:160, 1:320, and 1:640, respectively. ROC analysis revealed best test performance for distinction between healthy and ANA-related CTD populations at a serum dilution of 1 in 80. CONCLUSIONS: Antinuclear antibodies (ANA) positivity at low titers (1:40) is highly prevalent in healthy population (19.5%) as well as amongst mimics of CTD (26.4%). Our study suggests a higher screening dilution of 1:80 for ANA by IIF for diagnosis of CTD maybe better. Combination of 1:80 and 1:160 dilutions provides optimum sensitivity and specificity for diagnosis of ANA-related disorders.
BACKGROUND: Time and cost constraints lead to majority of clinical laboratories deviating away from an ideal practice of checking for antinuclear antibodies (ANAs) by indirect immunofluorescence (IIF) at multiple dilutions. Usage of screening dilution of 1:40 recommended by most manufacturers of commercial ANA kits results in numerous false positive-tests and misdiagnosis of connective tissue disorders (CTDs). We sought to study the ideal screening dilution for ANA by IIF for a diagnosis of ANA-related CTDs. METHODS: Serum samples of patients with ANA-related conditions (n = 233) and healthy controls (n = 154) were evaluated by IIF using Immuno Concepts Hep-2000 ® ANA kits at dilutions from 1:40 to 1:640. Accuracy for diagnosis of CTDs for each serum dilution was assessed by receiver operating curve (ROC) analysis. RESULTS: Antinuclear antibodies (ANA) positivity was observed in 19.5%, 10.4%, 4.55%, 0.65%, and 0% of healthy controls at dilutions of 1:40, 1:80, 1:160, 1:320, and 1:640, respectively. ANA positivity at 1:40 dilution was observed among 26.4% cases with mimics of CTDs. Prevalence of ANA positivity in ANA-related CTDs was 97.3%, 96.4%, 89.3%, 83.9%, and 71.4% at dilutions of 1:40, 1:80, 1:160, 1:320, and 1:640, respectively. ROC analysis revealed best test performance for distinction between healthy and ANA-related CTD populations at a serum dilution of 1 in 80. CONCLUSIONS: Antinuclear antibodies (ANA) positivity at low titers (1:40) is highly prevalent in healthy population (19.5%) as well as amongst mimics of CTD (26.4%). Our study suggests a higher screening dilution of 1:80 for ANA by IIF for diagnosis of CTD maybe better. Combination of 1:80 and 1:160 dilutions provides optimum sensitivity and specificity for diagnosis of ANA-related disorders.
Authors: E M Tan; T E Feltkamp; J S Smolen; B Butcher; R Dawkins; M J Fritzler; T Gordon; J A Hardin; J R Kalden; R G Lahita; R N Maini; J S McDougal; N F Rothfield; R J Smeenk; Y Takasaki; A Wiik; M R Wilson; J A Koziol Journal: Arthritis Rheum Date: 1997-09
Authors: Sonali Narain; Hanno B Richards; Minoru Satoh; Marlene Sarmiento; Richard Davidson; Jonathan Shuster; Eric Sobel; Paulette Hahn; Westley H Reeves Journal: Arch Intern Med Date: 2004 Dec 13-27
Authors: Maria Koshy; John Mathew; Reginald Alex; John Antony Jude; Ravikar Ralph; Thambu David Sudarsanam; Sowmya Sathyendra; J Visalakshi; John Victor Peter Journal: J Vector Borne Dis Date: 2018 Jan-Mar Impact factor: 1.688